Building a New Cancer Care Ecosystem: Liora’s Proton Therapy and LIXTE’s Drug Pipeline in Synergy
- LIXTE Biotechnology Holdings and the company’s subsidiary, Liora Technologies, both develop products that aim to improve outcomes for cancer patients
- Specifically, Liora’s Linac for Image Guided Hadron Therapy (“LiGHT”) System and LIXTE’s LB-100 work together to fight cancer
- As a result, the companies are building a new cancer care ecosystem that hopes to boost the effectiveness of treatments, while also help them be more accessible for a wider range of patients
Recently, LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT), a clinical-stage pharmaceutical company, acquired Liora Technologies, a company that is aiming to transform cancer care with innovative compact proton therapy.
Specifically, Liora has created the LiGHT System, which is believed to provide many advantages over other proton therapy methods and systems that are currently available. While it is smaller in size, the system can be deployed quickly and is much more cost-effective to build and use.
The system also eliminates mechanical energy degraders, reduces proton loss and enables more efficiency as it adjusts energy electronically. It also allows for much more precise dosing and lets you change energy levels much faster than many other methods.
The LiGHT system synergizes incredibly well with LIXTE’s lead clinical candidate and main product, LB-100, a proprietary small-molecule inhibitor of protein phosphatase 2A (“PP2A”) that boosts the activity and effectiveness of chemotherapy and immunotherapy. It has demonstrated a favorable safety profile in Phase 1 clinical trials and is supported by more than two dozen published preclinical and translational studies. The compound is currently being evaluated in multiple clinical programs targeting solid tumors with limited treatment options.
Together, the companies, and their flagship products and systems, are building a new cancer care ecosystem. Specifically, Liora’s radiotherapy technology complements LIXTE’s LB-100 approach.
The LiGHT System works to effectively destroy cancer cells by precisely delivering the right amount of radiation in the right spots. This synergizes well with LB-100, as the compound not only makes cancer cells more vulnerable to the radiation, but also helps to prevent these cancer cells from being able to repair themselves after being damaged.
Simply put, the LB-100 may weaken the cancer cells, thus boosting how well the radiation from the LiGHT System is able to damage them, while also preventing the cells from being able to recover after being damaged by the radiation.
As a result, the pair has the potential to become a multi-modal cancer care platform that helps patients enjoy more effective cancer treatments. The acquisition allows LIXTE to test the drug-device combo in trials and see just how much more effective and efficient the ecosystem may be than other currently available methods.
About LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT)
LIXTE Biotechnology Holdings is a clinical-stage pharmaceutical company that’s developing cancer therapies built around a novel biological target. Instead of introducing standalone treatments, the company is focused on enhancing the effectiveness of established cancer therapies and addressing challenges that limit outcomes in oncology.
For more information, visit the company website at https://lixte.com.
NOTE TO INVESTORS: The latest news and updates relating to LIXT are available in the company’s newsroom at https://nnw.fm/LIXT
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
- LIXTE Biotechnology Holdings and the company’s subsidiary, Liora Technologies, both develop products that aim to improve outcomes for cancer patients
- Specifically, Liora’s Linac for Image Guided Hadron Therapy (“LiGHT”) System and LIXTE’s LB-100 work together to fight cancer
- As a result, the companies are building a new cancer care ecosystem that hopes to boost the effectiveness of treatments, while also help them be more accessible for a wider range of patients
Recently, LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT), a clinical-stage pharmaceutical company, acquired Liora Technologies, a company that is aiming to transform cancer care with innovative compact proton therapy.
Specifically, Liora has created the LiGHT System, which is believed to provide many advantages over other proton therapy methods and systems that are currently available. While it is smaller in size, the system can be deployed quickly and is much more cost-effective to build and use.
The system also eliminates mechanical energy degraders, reduces proton loss and enables more efficiency as it adjusts energy electronically. It also allows for much more precise dosing and lets you change energy levels much faster than many other methods.
The LiGHT system synergizes incredibly well with LIXTE’s lead clinical candidate and main product, LB-100, a proprietary small-molecule inhibitor of protein phosphatase 2A (“PP2A”) that boosts the activity and effectiveness of chemotherapy and immunotherapy. It has demonstrated a favorable safety profile in Phase 1 clinical trials and is supported by more than two dozen published preclinical and translational studies. The compound is currently being evaluated in multiple clinical programs targeting solid tumors with limited treatment options.
Together, the companies, and their flagship products and systems, are building a new cancer care ecosystem. Specifically, Liora’s radiotherapy technology complements LIXTE’s LB-100 approach.
The LiGHT System works to effectively destroy cancer cells by precisely delivering the right amount of radiation in the right spots. This synergizes well with LB-100, as the compound not only makes cancer cells more vulnerable to the radiation, but also helps to prevent these cancer cells from being able to repair themselves after being damaged.
Simply put, the LB-100 may weaken the cancer cells, thus boosting how well the radiation from the LiGHT System is able to damage them, while also preventing the cells from being able to recover after being damaged by the radiation.
As a result, the pair has the potential to become a multi-modal cancer care platform that helps patients enjoy more effective cancer treatments. The acquisition allows LIXTE to test the drug-device combo in trials and see just how much more effective and efficient the ecosystem may be than other currently available methods.
About LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT)
LIXTE Biotechnology Holdings is a clinical-stage pharmaceutical company that’s developing cancer therapies built around a novel biological target. Instead of introducing standalone treatments, the company is focused on enhancing the effectiveness of established cancer therapies and addressing challenges that limit outcomes in oncology.
For more information, visit the company website at https://lixte.com.
NOTE TO INVESTORS: The latest news and updates relating to LIXT are available in the company’s newsroom at https://nnw.fm/LIXT
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
